Skip to content
Home » Medications » Repaglinide-  0.5 mg, 90 stk.

Repaglinide-  0.5 mg, 90 stk.

Short-acting insulin secretagogue

Description

Generic Name: Repaglinide
Brand Name: NovoNorm, Prandin
Drug Class: Meglitinide (Short-acting Insulin Secretagogue)


This is a prescription medicine, which requires a valid prescription!

Indications

  • Type 2 Diabetes Mellitus:
  • Used to improve postprandial blood glucose control in adults with type 2 diabetes, typically in combination with diet and exercise. Can be used alone or in combination with other antidiabetic medications (e.g., metformin, sulfonylureas, insulin).
Mechanism of Action

Repaglinide:

  • Stimulates the pancreas to release insulin by blocking ATP-dependent potassium channels in beta cells.
  • Has a rapid onset and short duration of action, targeting mealtime (postprandial) blood sugar spikes.
  • Insulin release is glucose-dependent, reducing the risk of prolonged hypoglycemia compared to sulfonylureas.
Dosage and Administration
  • Form: Oral tablet
  • Starting Dose: 0.5 mg before each main meal
  • Dose Adjustment: Based on blood glucose response; can increase gradually up to 4 mg per meal (maximum total daily dose: 16 mg)
  • Administer 15–30 minutes before meals; skip dose if skipping a meal
  • Not intended for use in type 1 diabetes or diabetic ketoacidosis
Side Effects
  • Common:
    • Hypoglycemia (especially if meals are delayed or skipped)
    • Headache
    • Upper respiratory tract infections
    • Joint or back pain
    • GI symptoms: nausea, diarrhea
  • Serious (rare):
    • Severe hypoglycemia (if overdosed or in renal/liver impairment)
    • Liver enzyme elevation (monitor if symptoms arise)
    • Hypersensitivity reactions (rash, itching)
Contraindications
  • Type 1 diabetes or diabetic ketoacidosis
  • Severe liver dysfunction
  • Concomitant use with gemfibrozil
  • Hypersensitivity to repaglinide or excipients

Information

Warnings and Precautions

  • Risk of hypoglycemia increases with missed meals or excessive doses
  • Use caution in elderly or those with hepatic impairment
  • Not for use with gemfibrozil (increased repaglinide levels and risk of hypoglycemia)
  • Monitor blood glucose regularly

Drug Interactions

  • Gemfibrozil: Contraindicated – significantly increases repaglinide levels
  • Beta-blockers: May mask hypoglycemia symptoms
  • CYP3A4/CYP2C8 inhibitors (e.g., clarithromycin, ketoconazole): May increase drug levels
  • CYP inducers (e.g., rifampin): May decrease efficacy
  • Insulin or other secretagogues: Additive hypoglycemia risk

Pregnancy & Lactation

  • Pregnancy: Use only if clearly needed (insufficient data)
  • Breastfeeding: Not recommended due to lack of safety data

Request Now

Please enable JavaScript in your browser to complete this form.
Terms & Conditions

Direct Enquiries
For any inquiries, please feel free to contact us directly via email at the link below.
pharmacy@doctorworld.eu

DISCLAIMER

PLEASE AVOID SELF-DIAGNOSIS AND SELF-MEDICATION!

Our website content is posted for informational purposes only. It is not intended to be used for primary diagnoses-making and should not replace a consultation with a professional health care provider. If you have any health issues or complaints, please consult your primary physician.

Health care data provided for informational purposes is not an alternative to an in-person physician consultation.